EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Precision Targeting of Myeloid Cells via Peptide Dendrimer‐Lipid Nanocarriers: A Novel Platform for Potent Cancer Immunotherapies

Lawrence James Billing iD, Liam Martin, Tristan Henser-Brownhill, Parisa Samangouei, Adam Leach, Phoebe Knight, Marina Apostolidou, Aaqib Ladak, Benita Nagel, Albert Kwok

Advanced Science · 2025

DOI: 10.1002/advs.202514417 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Lawrence James Billing und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nuntius Therapeutics Limited, London, W10 5JJ, UK. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, Drug Carriers, Myeloid Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Selective targeting of myeloid cells (MCs) holds therapeutic potential as an immuno‐oncology approach. However, MC targeting using existing gene delivery platforms faces many barriers to clinical use, such as production scalability and off‐target delivery to the liver and non‐MCs. Here, a novel peptide dendrimer‐lipid (PDL) nanocarrier for systemic administration, which overcomes many of these barriers, is characterized. This MC targeting nanocarrier (MCTN) is self‐assembling, de‐targets the liver, and selectively targets the spleen and MCs within the tumor microenvironment (TME). MCTN is validated as a cancer vaccine platform utilizing full‐length antigens, generating robust immune responses with broad HLA‐haplotype coverage. Finally, using a payload encoding constitutively active interferon regulatory factor 5 (IRF5), MCTN is found to suppress solid tumor growth and modulate the TME by improving CD8+ T‐cell infiltration while depleting immunosuppressive cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesLipidsDrug CarriersMyeloid CellsImmunotherapyNeoplasmsDendrimersPeptidesTumor MicroenvironmentCancer VaccinesHumansAnimalsMiceMacrophagesNucleic AcidsCell LineFemaleMice, Inbred C57BLNeoplasms, ExperimentalVaccine EfficacyLiposomes

Stichwörter der Autor:innen

RNA therapiesimmunotherapyimmuno‐oncologymRNA vaccinesnanomedicine

Substanzen

Lipid NanoparticlesLipidsDrug CarriersDendrimersPeptidesCancer VaccinesNucleic AcidsLiposomes

Autor:innen und Institutionen

  • Nuntius Therapeutics Limited, London, W10 5JJ, UK.

ORCID-Profile: Lawrence James Billing

Zitieren

APA

Billing, L. J., Martin, L., Henser-Brownhill, T., Samangouei, P., Leach, A., Knight, P., Apostolidou, M., Ladak, A., Nagel, B., & Kwok, A. (2025). Precision Targeting of Myeloid Cells via Peptide Dendrimer‐Lipid Nanocarriers: A Novel Platform for Potent Cancer Immunotherapies. Advanced Science. https://doi.org/10.1002/advs.202514417

Vancouver

Billing LJ, Martin L, Henser-Brownhill T, Samangouei P, Leach A, Knight P, et al. Precision Targeting of Myeloid Cells via Peptide Dendrimer‐Lipid Nanocarriers: A Novel Platform for Potent Cancer Immunotherapies. Advanced Science. 2025. doi:10.1002/advs.202514417

BibTeX
@article{Billing2025,
  author = {Billing, Lawrence James and Martin, Liam and Henser-Brownhill, Tristan and Samangouei, Parisa and Leach, Adam and Knight, Phoebe and Apostolidou, Marina and Ladak, Aaqib and Nagel, Benita and Kwok, Albert},
  title = {Precision Targeting of Myeloid Cells via Peptide Dendrimer‐Lipid Nanocarriers: A Novel Platform for Potent Cancer Immunotherapies},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202514417}
}
Kostenlos starten →